CA3226492A1 - Bicyclic peptide inhibitors of interleukin-23 receptor - Google Patents
Bicyclic peptide inhibitors of interleukin-23 receptor Download PDFInfo
- Publication number
- CA3226492A1 CA3226492A1 CA3226492A CA3226492A CA3226492A1 CA 3226492 A1 CA3226492 A1 CA 3226492A1 CA 3226492 A CA3226492 A CA 3226492A CA 3226492 A CA3226492 A CA 3226492A CA 3226492 A1 CA3226492 A1 CA 3226492A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- phe
- pen
- cyano
- thp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163221854P | 2021-07-14 | 2021-07-14 | |
| US63/221,854 | 2021-07-14 | ||
| PCT/US2022/037202 WO2023288017A2 (en) | 2021-07-14 | 2022-07-14 | Bicyclic peptide inhibitors of interleukin-23 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3226492A1 true CA3226492A1 (en) | 2023-01-19 |
Family
ID=84920518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3226492A Pending CA3226492A1 (en) | 2021-07-14 | 2022-07-14 | Bicyclic peptide inhibitors of interleukin-23 receptor |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240352073A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4370532A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024525723A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240034223A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117980320A (cg-RX-API-DMAC7.html) |
| AR (1) | AR126457A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022310347A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3226492A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024000761A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202321275A (cg-RX-API-DMAC7.html) |
| UY (1) | UY39858A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023288017A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4091624A1 (en) | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| CA2949215C (en) | 2014-05-16 | 2023-03-14 | Protagonist Therapeutics, Inc. | .alpha.4.beta.7 integrin thioether peptide antagonists |
| SG10201810154WA (en) | 2014-07-17 | 2018-12-28 | Protagonist Therapeutics Inc | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| WO2018022937A1 (en) | 2016-07-27 | 2018-02-01 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases |
| WO2019157268A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| MX2022008740A (es) | 2020-01-15 | 2022-09-23 | Janssen Biotech Inc | Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias. |
| AU2021383828A1 (en) | 2020-11-20 | 2023-07-06 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of interleukin-23 receptor |
| KR20240034224A (ko) | 2021-07-14 | 2024-03-13 | 얀센 바이오테크 인코포레이티드 | 인터류킨-23 수용체의 지질화된 펩티드 억제제 |
| EP4652181A1 (en) * | 2023-01-16 | 2025-11-26 | Janssen Pharmaceutica NV | Polycyclic peptide inhibitors of interleukin-23 receptor |
| EP4471049A1 (en) | 2023-06-01 | 2024-12-04 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| EP4471048A1 (en) | 2023-06-01 | 2024-12-04 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| CN121909205A (zh) | 2023-09-08 | 2026-04-21 | 赛诺菲 | 作为选择性il-23受体抑制剂的新型肽 |
| CN121794283A (zh) | 2023-09-08 | 2026-04-03 | 赛诺菲 | 作为选择性il-23受体抑制剂的新型肽 |
| WO2025076414A1 (en) * | 2023-10-06 | 2025-04-10 | The Children's Medical Center Corporation | Compositions and methods for selecting a subject for inflammatory bowel disease treatment |
| WO2026013260A1 (en) | 2024-07-12 | 2026-01-15 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| WO2026026815A1 (zh) * | 2024-07-30 | 2026-02-05 | 西藏海思科制药有限公司 | 白介素-23受体的肽抑制剂及其用途 |
| WO2026041110A1 (zh) * | 2024-08-22 | 2026-02-26 | 上海瀚辰星泰医药科技有限公司 | 一种多肽化合物及其应用 |
| WO2026138829A1 (zh) * | 2024-12-23 | 2026-07-02 | 上海医药集团股份有限公司 | 多肽抑制剂及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201810154WA (en) * | 2014-07-17 | 2018-12-28 | Protagonist Therapeutics Inc | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| WO2016054445A1 (en) * | 2014-10-01 | 2016-04-07 | Protagonist Therapeutics, Inc. | Novel cyclic monomer and dimer peptides having integrin antagonist activity |
| HK1257747A1 (zh) * | 2015-07-15 | 2019-10-25 | Protagonist Therapeutics Inc. | 白细胞介素-23受体的肽抑制剂以及其治疗炎症性疾病的用途 |
| CA3046171A1 (en) * | 2016-12-06 | 2018-06-14 | Stichting Voor De Technische Wetenschappen | Multicyclic peptides and methods for their preparation |
| WO2019034866A1 (en) * | 2017-08-14 | 2019-02-21 | Bicyclerd Limited | BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF |
| MX2020006290A (es) * | 2017-12-15 | 2020-12-03 | Janssen Biotech Inc | Dinucleotidos ciclicos como agonistas de sting. |
| CA3104418A1 (en) * | 2018-07-12 | 2020-01-16 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| AU2020311395A1 (en) * | 2019-07-10 | 2022-02-03 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| TWI860386B (zh) * | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
-
2022
- 2022-07-14 JP JP2024501737A patent/JP2024525723A/ja active Pending
- 2022-07-14 CN CN202280062001.1A patent/CN117980320A/zh active Pending
- 2022-07-14 WO PCT/US2022/037202 patent/WO2023288017A2/en not_active Ceased
- 2022-07-14 MX MX2024000761A patent/MX2024000761A/es unknown
- 2022-07-14 CA CA3226492A patent/CA3226492A1/en active Pending
- 2022-07-14 TW TW111126553A patent/TW202321275A/zh unknown
- 2022-07-14 EP EP22842895.9A patent/EP4370532A4/en active Pending
- 2022-07-14 UY UY0001039858A patent/UY39858A/es unknown
- 2022-07-14 US US18/579,033 patent/US20240352073A1/en active Pending
- 2022-07-14 AU AU2022310347A patent/AU2022310347A1/en not_active Abandoned
- 2022-07-14 AR ARP220101855A patent/AR126457A1/es unknown
- 2022-07-14 KR KR1020247004796A patent/KR20240034223A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4370532A4 (en) | 2025-09-03 |
| KR20240034223A (ko) | 2024-03-13 |
| TW202321275A (zh) | 2023-06-01 |
| CN117980320A (zh) | 2024-05-03 |
| AR126457A1 (es) | 2023-10-11 |
| UY39858A (es) | 2023-02-28 |
| JP2024525723A (ja) | 2024-07-12 |
| WO2023288017A3 (en) | 2023-03-09 |
| MX2024000761A (es) | 2024-04-18 |
| US20240352073A1 (en) | 2024-10-24 |
| WO2023288017A2 (en) | 2023-01-19 |
| AU2022310347A1 (en) | 2024-02-29 |
| EP4370532A2 (en) | 2024-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12478617B2 (en) | Lipidated peptide inhibitors of interleukin-23 receptor | |
| CA3226539A1 (en) | Peptide inhibitors of interleukin-23 receptor | |
| EP4370532A2 (en) | Bicyclic peptide inhibitors of interleukin-23 receptor | |
| JP7819087B2 (ja) | インターロイキン-23受容体のペプチド阻害剤および炎症性疾患を治療するためのそれらの使用 | |
| JP7659015B2 (ja) | 免疫調節剤としての1,2,4-オキサジアゾールおよびチアジアゾール化合物 | |
| TWI882061B (zh) | 介白素-23受體之肽抑制劑及其治療發炎性疾病之用途 | |
| JP7670605B2 (ja) | インターロイキン-23受容体のペプチド阻害剤および炎症性疾患を治療するためのその使用 | |
| JP2025134806A (ja) | インターロイキン23受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用 | |
| JP2022540154A (ja) | インターロイキン-23受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用 | |
| JP2018507885A (ja) | 免疫調節剤としての1,3,4−オキサジアゾールおよびチアジアゾール化合物 | |
| KR20260007614A (ko) | 인터루킨-23 수용체의 펩타이드 억제제의 제조 및 이의 용도 | |
| CN119255822A (zh) | 靶向循环蛋白的选择性降解的双功能小分子 | |
| KR20250028290A (ko) | 선택적 il-23 수용체 길항제로서의 새로운 펩티드 | |
| CN107602450A (zh) | 氨基酸骨架类新型cxcr4拮抗剂及其制备与生物医学应用 | |
| HK40111925A (en) | Lipidated peptide inhibitors of interleukin-23 receptor | |
| JPWO2002102833A1 (ja) | 新規エンドモルフィン誘導体 | |
| CN121449688A (zh) | 白介素-23受体的肽抑制剂及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250603 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250603 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260602 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260602 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260710 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260710 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260710 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260731 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260731 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260731 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260731 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260731 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260731 |